OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Response rates to G12C inhibitors in KRAS G12C-mutant colorectal cancer are lower than in NSCLC.
“Response rates in KRAS G12C -mutant CRC are even lower (11).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works
Mukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105 · see citing works
KRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76 · see citing works
- Authors
- Falchook, G., Li, B. T., Marrone, K. A., Bestvina, C. M., Langer, C. J., Krauss, J. C., Strickler, J. H., Meloni, A., Dai, T., Varrieur, T., & Hong, D. S.
- Affiliations
- HealthONE (US)
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- University of Chicago (US)
- University of Pennsylvania (US)
- University of Michigan (US)
- Duke Medical Center (US)
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 17
- Issue
- 9
- Pages
- S8
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W4296771041
- Cited by
- 56
- References
- 0
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 11 · 2023: 9 · 2022: 4
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- sotorasib, SHP2 inhibitors, KRAS G12C mutation, non-small cell lung cancer, solid tumors, receptor tyrosine kinase inhibitors, Ras signaling, drug resistance, combination therapy, xenograft mouse model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
